Multiple Sclerosis
An autoimmune disease of the central nervous system where the body's immune system attacks myelin, causing varied neurological symptoms.
Emergency Management: Status epilepticus (rare but possible). Severe dysphagia leading to aspiration pneumonia requiring emergency airway management/antibiotics.
Multiple sclerosis is an immune-mediated, chronic inflammatory and neurodegenerative disease of the central nervous system. It is characterized by focal destruction of myelin sheaths (demyelination) and axonal damage in the brain and spinal cord, leading to impaired neurological signaling.
Detailed Overview
The disease manifests as episodic neurological deficits (relapses) that typically evolve into a progressive decline over time. The pathology involves autoreactive T cells crossing the blood-brain barrier, triggering an inflammatory cascade that damages oligodendrocytes. Plaques or lesions form in the white and grey matter. MS presents heterogeneously with visual, motor, sensory, and autonomic symptoms.
Epidemiology & Demographics
Prevalence is roughly 1 in 1000 in North America and Northern Europe. Median age of onset is 28-31 years. Women are affected 2.5 to 3 times more frequently than men.
Etiological Mechanism
Considered a complex interplay of genetic susceptibility (HLA-DRB1*1501 allele) and environmental triggers (Epstein-Barr Virus infection, low Vitamin D levels, smoking).
Primary Causes
An autoimmune response targeting central nervous system antigens (e.g., myelin basic protein), initiated by molecular mimicry or bystander activation after viral infections.
Autoreactive CD4+ Th1 and Th17 cells breach the blood-brain barrier and secrete pro-inflammatory cytokines (IFN-gamma, IL-17). This recruits macrophages and B cells. Macrophages strip myelin from axons. B cells produce oligoclonal immunoglobulins. Myelin loss impairs saltatory conduction, causing conduction block. Over time, chronic inflammation leads to irreversible axonal transection and brain atrophy.
Diagnostic Criteria & Guidelines
Diagnosis is based on the McDonald Criteria (2017 revision), requiring evidence of dissemination in space (DIS) - >=1 T2 lesion in >=2 of 4 MS-typical regions (periventricular, cortical/juxtacortical, infratentorial, spinal cord) AND dissemination in time (DIT) - simultaneous presence of enhancing and non-enhancing lesions, or a new lesion on follow-up MRI, or CSF-specific oligoclonal bands.
Disease-Modifying Therapies (DMTs). For highly active disease: Ocrelizumab (600 mg IV every 6 months) or Natalizumab (300 mg IV every 4 weeks). For moderate disease: Dimethyl fumarate (240 mg PO BID) or Teriflunomide (14 mg PO daily). Acute exacerbations: IV Methylprednisolone 1000 mg daily for 3-5 days.
Second-Line & Adjunctive Therapy
Alemtuzumab (12 mg/day IV for 5 days year 1, 3 days year 2) or Cladribine. Autologous hematopoietic stem cell transplantation (aHSCT) for aggressive, treatment-refractory relapsing disease.
Surgical & Procedural Management
Rarely indicated for MS directly. Intrathecal baclofen pump placement for severe, medically refractory spasticity.
Patient Counseling & Advice
Counsel on avoiding extreme heat, which can temporarily exacerbate symptoms (Uhthoff phenomenon). Discuss family planning, as some DMTs (teriflunomide, cladribine) are highly teratogenic.
Follow-Up & Monitoring Schedule
Annual brain MRI (and spinal cord MRI if symptomatic) to assess for silent radiological activity. John Cunningham (JC) virus serology every 6 months if on Natalizumab to assess PML risk.
Preventive Strategies
Adequate vitamin D supplementation in childhood and adolescence, preventing childhood obesity, and avoiding smoking.
Life expectancy is reduced by approximately 7 years compared to the general population. 50% of patients require a walking aid 15 years after diagnosis if untreated, but outcomes have drastically improved with modern DMTs.